Newborn screening for SCID: where are we now? Expert Rev Clin Immunol 2014 Dec;10(12):1649-57
Date
11/13/2014Pubmed ID
25387596DOI
10.1586/1744666X.2014.980816Scopus ID
2-s2.0-84911169687 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
Newborn screening (NBS) for severe T-cell lymphopenia/severe combined immunodeficiency using the T-cell receptor excision circle assay continues to expand in the USA and worldwide. Here, we will review why severe combined immunodeficiency is an excellent case for NBS, the outcomes of the first 6 years of screening, and dilemmas surrounding screening and management of infants detected by NBS. We will also discuss the future of NBS for primary immunodeficiencies.
Author List
Buelow BJ, Routes JM, Verbsky JWAuthors
Becky J. Buelow MD Associate Professor in the Pediatrics department at Medical College of WisconsinJames Verbsky MD, PhD Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Early DiagnosisHumans
Infant, Newborn
Neonatal Screening
Severe Combined Immunodeficiency